The Next Generation of Gene Therapy Companies
This article was originally published in Start Up
Executive Summary
Despite problems with delivery and duration of expression, gene therapy still interests investors and entrepreneurs, who are pursuing new approaches.You may also be interested in...
Mirus Corporation
Gene Therapy. Mirus is exploring technology for transfection reagents and has patents pending on certain protein, lipid and polyamine combinations for gene delivery. These formulations are designed to deliver DNA to cells with minimal toxicitiy. Mirus is already selling off-the-shelf transfection reagents which have been developed for gene transfer into cells in culture.
Calydon Inc.
Gene Therapy. Calydon is going after prostate cancer by delivering a prostate tissue-specific enhancer (PSE) gene to epithelial cells using an attenuated adenoviral vector.
Bavarian Nordic Research Institute GmbH
Gene Therapy. Bavarian Nordic avoids concerns about the pathogenicity of viral vectors with treatments based on modified vaccinia ankara (MVA) vectors and retroviral promoter conversion vectors. The company's MVA programs are focused on cancer, HIV infection and Dengue fever. It is developing {ProCon} for treatment of cancers of the breast and pancreas and potentially restenosis.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports